Page 2 - catalogue aanglais
P. 2
GenEvolutioN : toxicity of targeted personalized
therapies and innovative techniques/approaches.
Established in February 2017, GenEvolutioN SAS Share
Capital €20 000dedicated in the following activities:
Research & development for pharmaceutical,
cosmetics and chemical companies.
Health: develop personalized medical treatment,
cellular therapy.
Services for in vitro tests on biological systems and
cytogenetic analyzes.
Scientificconsulting.
